Merck KGaA’s $1.1B Silence Therapeutics Buyout Brings RNA Drug for Rare Blood Cancer

Merck KGaA agreed to acquire Silence Therapeutics for $1.1B, gaining its lead drug divesiran, which is in development for polycythemia vera, a rare blood cancer. The deal includes Silence's siRNA platform technology and is expected to close in Q1 2027, pending regulatory and shareholder approval. According to Silence, the acquisition follows a competitive process and aligns with Merck's strategy to expand its rare disease portfolio.

Original reporting
Published Oct 19, 2026, 8:27 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 19, 2026, 9:15 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Merck KGaA’s $1.1B Silence Therapeutics Buyout Brings RNA Drug for Rare Blood Cancer — source image
Decision brief

The 30-second read

High
01

Why it matters

The deal adds a late‑stage asset and siRNA platform to Merck's rare‑disease strategy, potentially enhancing its competitive position against Takeda and PharmaEssentia.

02

Market read

First‑report M&A of over $1 billion in biotech, likely moving both stocks and influencing sector sentiment.

03

What to watch

Regulatory approval risk for divesiran and integration challenges could delay value realization.

Relevance 9/10Novelty 9/10Timing: immediate today

Background

Merck KGaA, a German pharma group, announced a cash acquisition of UK‑based Silence Therapeutics, bringing in a Phase‑2‑validated siRNA drug for polycythemia vera.

Market effects

Strengthens the biotech siRNA segment and may spur further M&A activity in rare‑disease space.

European biotech valuations could see uplift as a high‑profile German firm expands its pipeline.

Adds to the global trend of large pharma acquiring niche biotech assets to fill pipeline gaps.

Counterpoint

Merck may overpay if Phase 3 fails, leading to a future write‑down and share price pressure.

Key entities

  • Merck KGaA

    German pharmaceutical company acquiring Silence Therapeutics.

  • Silence Therapeutics

    UK biotech developing the siRNA drug divesiran for polycythemia vera.

Related articles

$MRKHigh

Why Merck (MRK) Stock Is Down Today

Merck (MRK) shares fell 3.8% after the company discontinued the BELLWAVE clinical program for nemtabrutinib, citing potential risks outweighing benefits in a Phase 3 trial. The decision impacts multiple studies, marking a pipeline setback for the drugmaker. Merck's latest earnings report had shown revenue growth and pipeline activity before this development.

$MRKHigh

Merck wins all 14 U.S. patent reviews against Halozyme

Merck (MSD) won all 14 U.S. patent reviews against Halozyme, securing its Keytruda Qlex cancer immunotherapy's subcutaneous injection technology. The Patent Trial and Appeal Board ruled all challenged claims unpatentable. Keytruda Qlex sales reached $830M in Q3, 9.7% of total Keytruda sales. Halozyme may appeal, and a patent infringement lawsuit is ongoing.